2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Pathogenesis, CHIP, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3600 Mitoxantrone hydrochloride liposome combined with coep (CMOEP) as first-line therapy for peripheral T-cell lymphoma: Interim Results of the prospective, multicenter, phase II compass trial

Jingwei Yu, MD, Jiesong Wang2, Xiaobing Huang, MD3, Lintao Bi, MD, PhD4, Lihua Qiu5, Hongwei Xue6, Dong Song7, Liqun Zou8, Zhengzi Qian9, Jin Zhang10, Yu Li11, Yao Liu, MD, PhD12, Lanfang Li13, Xianming Liu14, Xiuhua Sun, MD15, Yan Huang16, Haisheng Liu17, Qing-Yuan Zhang, MD18, Huilai Zhang, PhD19
1 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
2 College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China
3 Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China
4 The Third Bethune Hospital of Jilin University, Changchun, China
5 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
6 The Affiliated Hospital of Qingdao University, Qingdao, China
7 Shanxi Bethune Hospital, Taiyuan, China
8 West China Hospital, Sichuan University, Chengdu, China
9 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
10 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
11 The Second Affiliated Hospital of Nanchang University, Nanchang, China
12 Chongqing University Cancer Hospital, Chongqing, China
13 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
14 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
15 The Second Hospital of Dalian Medical University, Dalian, China
16 Jiangxi Cancer Hospital, Nanchang, China
17 The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
18 Harbin Medical University Cancer Hospital, Harbin, China
19 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Background

Peripheral T-cell lymphoma (PTCL) represents a heterogeneous group of aggressive non-Hodgkin lymphomas. Conventional first-line CHOP/CHOEP regimens deliver limited efficacy with unfavorable long-term outcomes, and the cardiotoxicity of conventional anthracyclines restricts their clinical application. Mitoxantrone hydrochloride liposome (Lipo-MIT) is a novel liposomal anthracycline formulation that achieves targeted accumulation in tumor tissues while substantially reducing cardiotoxicity. The COMPASS trial (NCT06433362) was designed to evaluate the efficacy and safety of the CMOEP regimen (mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, etoposide, and prednisone) as first-line therapy for patients with newly diagnosed PTCL. Preliminary results of the CMOEP regimen were previously presented at the 2026 ESMO Annual Meeting. Herein, we report updated efficacy and safety analyses from a larger, more mature patient cohort.

Methods

This was a prospective, single-arm phase II clinical trial. Eligible patients were aged 18–70 years with histologically confirmed PTCL. Patients received Lipo-MIT 18 mg/m² on Day 1, plus COEP (cyclophosphamide 750 mg/m² on Day 1, vincristine 1.4 mg/m² on Day 1, etoposide 60 mg/m² on Days 1–3, prednisone 100 mg on Days 1–5) in 21-day cycles for up to 6 cycles. The primary endpoint was complete response rate (CRR). Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety profile. Efficacy was assessed per the Lugano 2014 criteria, and adverse events were graded according to CTCAE version 5.0.

Results

As of July 28, 2026, a total of 59 patients with newly diagnosed PTCL were enrolled, with a median follow-up duration of 6.9 months (range: 0.03–23.6 months). The median age was 58 years (range: 21–70 years), 59.3% of patients were male, 83.1% had stage III–IV disease, and 42.4% had an International Prognostic Index (IPI) score of 3–5 (high-risk). The predominant pathological subtypes were PTCL-not otherwise specified (PTCL-NOS, 40.7%) and angioimmunoblastic T-cell lymphoma (AITL, 37.3%). 

Among the 48 efficacy-evaluable patients, the best CRR reached 58.3% (28/48) with a ORR of 91.7% (44/48). Among the 42 patients who completed treatment, the CRR was 59.5% (25/42) and the ORR was 92.9% (39/42). Subgroup analysis showed that patients with low-risk IPI (0–2) had a significantly higher CRR than those with high-risk IPI (3–5) (75.0% vs 35.3%, P=0.017). Consistent efficacy benefits were observed across subgroups stratified by age, sex, pathological subtype and tumor stage.

In the survival analysis, median PFS and median OS were not yet reached with a 6-month PFS rate of 88.9% and a 6-month OS rate of 96.9%. The most common Grade ≥3 treatment-related adverse events (TRAEs) were lymphocytopenia (40.7%), neutropenia (40.7%), leukopenia (39.0%), anemia (13.6%), thrombocytopenia (10.2%), and pneumonia (8.5%). No treatment-related deaths were reported. Cardiac adverse events were infrequent and predominantly mild in severity.

Conclusions

This updated interim analysis of the COMPASS phase II trial demonstrates that the CMOEP regimen exhibits promising antitumor activity with a manageable safety profile in newly diagnosed PTCL, supporting further clinical investigation.
Jingwei Yu, MD: No relevant conflicts of interest to declare.